

## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Single Technology Appraisal

## Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma after 2 or more systemic treatments (review of TA987) [ID6619]

## Draft Stakeholder list

Consultees	Commentators (no right to submit or appeal)
<u>Company</u> <ul style="list-style-type: none"> <li>Bristol-Myers Squibb (lisocabtagene maraleucel)</li> </ul> <u>Patient/carer groups</u> <ul style="list-style-type: none"> <li>African Caribbean Leukaemia Trust</li> <li>Anthony Nolan</li> <li>Black Health Agency for Equality</li> <li>Blood Cancer UK</li> <li>Cancer Black Care</li> <li>Cancer52</li> <li>DKMS</li> <li>Helen Rollason Cancer Charity</li> <li>Independent Cancer Patients Voice</li> <li>Kevin Kararwa Leukaemia Trust</li> <li>Leukaemia Cancer Society</li> <li>Leukaemia Care</li> <li>Lymphoma Action</li> <li>Macmillan Cancer Support</li> <li>Maggie's Centres</li> <li>Marie Curie</li> <li>South Asian Health Foundation</li> <li>Specialised Healthcare Alliance</li> <li>Tenovus Cancer Care</li> <li>WMUK</li> </ul> <u>Healthcare professional groups</u> <ul style="list-style-type: none"> <li>Association of Cancer Physicians</li> <li>British Blood Transfusion Society</li> <li>British Committee for Standards in Haematology</li> <li>British Geriatrics Society</li> <li>British Institute of Radiology</li> <li>British Oncology Pharmacy Association</li> <li>British Psychosocial Oncology Society</li> </ul>	<u>General</u> <ul style="list-style-type: none"> <li>All Wales Therapeutics &amp; Toxicology Centre</li> <li>Allied Health Professionals Federation</li> <li>Board of Community Health Councils in Wales</li> <li>British National Formulary</li> <li>Care Quality Commission</li> <li>Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>Healthcare Improvement Scotland</li> <li>Medicines and Healthcare products Regulatory Agency</li> <li>National Association of Primary Care</li> <li>National Pharmacy Association</li> <li>NHS Confederation</li> <li>Scottish Medicines Consortium</li> <li>Welsh Government</li> <li>Welsh Health Specialised Services Committee</li> </ul> <u>Comparator companies</u> <ul style="list-style-type: none"> <li>AbbVie (epcoritamab)</li> <li>Accord Healthcare (carboplatin, cisplatin, cytarabine, gemcitabine)</li> <li>Advanz Pharma (dexamethasone)</li> <li>Amarox (cisplatin, oxaliplatin)</li> <li>AS Kalceks (dexamethasone, oxaliplatin)</li> <li>Aspen (dexamethasone)</li> <li>Aspire Pharma (dexamethasone)</li> <li>Baxter Healthcare (ifosfamide)</li> <li>Celltrion Healthcare UK (rituximab)</li> <li>Chemidex Pharma (dexamethasone)</li> </ul>

Draft stakeholder list for the evaluation of Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma after 2 or more systemic treatments (review of TA987) [ID6619]

Issue date: September 2025

© National Institute for Health and Care Excellence 2024. All rights reserved.

Page 1 of 4

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> <li>British Society for Haematology</li> <li>Cancer Research UK</li> <li>Royal College of General Practitioners</li> <li>Royal College of Nursing</li> <li>Royal College of Pathologists</li> <li>Royal College of Physicians</li> <li>Royal College of Radiologists</li> <li>Royal Pharmaceutical Society</li> <li>Royal Society of Medicine</li> <li>Society and College of Radiographers</li> <li>UK Clinical Pharmacy Association</li> <li>UK Cutaneous Lymphoma Group</li> <li>UK Oncology Nursing Society</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>Department of Health and Social Care</li> <li>NHS England</li> </ul>	<ul style="list-style-type: none"> <li>Dr. Reddy's Laboratories (UK) (bendamustine, rituximab)</li> <li>Ennogen Healthcare International (dexamethasone)</li> <li>Gilead Sciences (axicabtagene ciloleucel)</li> <li>Glenmark Pharmaceuticals (dexamethasone)</li> <li>Hameln Pharma (dexamethasone)</li> <li>Hospira UK (carboplatin, cisplatin, cytarabine, dexamethasone, gemcitabine)</li> <li>Jazz Pharmaceuticals UK (cytarabine)</li> <li>KrKa UK (dexamethasone)</li> <li>Martindale Pharma (dexamethasone)</li> <li>Medac Pharma (epirubicin, oxaliplatin)</li> <li>Napp Pharmaceuticals (rituximab)</li> <li>Neon Healthcare (etoposide)</li> <li>Novartis Pharmaceuticals UK (dexamethasone)</li> <li>Panpharma UK (dexamethasone)</li> <li>Pfizer (cytarabine, epirubicin, methylprednisolone, rituximab)</li> <li>Rayner Pharmaceuticals (dexamethasone)</li> <li>Roche Products (rituximab, glofitamab, polatuzumab vedotin)</li> <li>Rosemont Pharmaceuticals (dexamethasone)</li> <li>Sandoz (cisplatin, rituximab)</li> <li>Seacross Pharmaceuticals (bendamustine, epirubicin, oxaliplatin)</li> <li>Sun Pharmaceutical (gemcitabine, oxaliplatin)</li> <li>Swedish Orphan Biovitrum (loncastuximab tesirine)</li> <li>Synchrony Pharma (dexamethasone, gemcitabine)</li> <li>Thame Laboratories (dexamethasone)</li> <li>Thea Pharmaceuticals (dexamethasone)</li> <li>Wockhardt UK (dexamethasone)</li> </ul>

Consultees	Commentators (no right to submit or appeal)
	<ul style="list-style-type: none"> <li>• Zentiva (dexamethasone)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• Cochrane Haematological Malignancies Group</li> <li>• Cochrane UK</li> <li>• Genomics England</li> <li>• Institute of Cancer Research</li> <li>• Leukaemia Busters</li> <li>• Leukaemia UK</li> <li>• Lymphoma Research Trust</li> <li>• MRC Clinical Trials Unit</li> <li>• National Cancer Research Institute High Grade Lymphoma Subgroup</li> <li>• National Institute for Health Research</li> </ul> <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> <li>• Public Health Wales</li> <li>• UK Health Security Agency</li> </ul>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

### Definitions:

#### Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient

Draft stakeholder list for the evaluation of Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma after 2 or more systemic treatments (review of TA987) [ID6619]

Issue date: September 2025

© National Institute for Health and Care Excellence 2024. All rights reserved.

Page 3 of 4

organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

### Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

---

<sup>1</sup> Non company consultees are invited to submit statements relevant to the group they are representing.